Insulet (PODD) Competitors $314.52 -5.86 (-1.83%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$312.97 -1.55 (-0.49%) As of 10/10/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PODD vs. BDX, IDXX, EW, RMD, DXCM, STE, HOLX, BAX, MASI, and GMEDShould you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), ResMed (RMD), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Baxter International (BAX), Masimo (MASI), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry. Insulet vs. Its Competitors Becton, Dickinson and Company IDEXX Laboratories Edwards Lifesciences ResMed DexCom STERIS Hologic Baxter International Masimo Globus Medical Insulet (NASDAQ:PODD) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends. Which has more risk and volatility, PODD or BDX? Insulet has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Does the media refer more to PODD or BDX? In the previous week, Becton, Dickinson and Company had 18 more articles in the media than Insulet. MarketBeat recorded 33 mentions for Becton, Dickinson and Company and 15 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.22 beat Insulet's score of 1.02 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 26 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer PODD or BDX? Insulet currently has a consensus price target of $347.67, suggesting a potential upside of 10.54%. Becton, Dickinson and Company has a consensus price target of $205.40, suggesting a potential upside of 10.19%. Given Insulet's stronger consensus rating and higher possible upside, equities analysts clearly believe Insulet is more favorable than Becton, Dickinson and Company.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insulet 0 Sell rating(s) 3 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 2.85Becton, Dickinson and Company 0 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has stronger earnings and valuation, PODD or BDX? Becton, Dickinson and Company has higher revenue and earnings than Insulet. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsulet$2.07B10.69$418.30M$3.2995.60Becton, Dickinson and Company$21.39B2.50$1.71B$5.5633.53 Is PODD or BDX more profitable? Insulet has a net margin of 10.01% compared to Becton, Dickinson and Company's net margin of 7.51%. Insulet's return on equity of 23.78% beat Becton, Dickinson and Company's return on equity.Company Net Margins Return on Equity Return on Assets Insulet10.01% 23.78% 9.30% Becton, Dickinson and Company 7.51%16.23%7.46% Do institutionals and insiders hold more shares of PODD or BDX? 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryInsulet beats Becton, Dickinson and Company on 10 of the 16 factors compared between the two stocks. Get Insulet News Delivered to You Automatically Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PODD vs. The Competition Export to ExcelMetricInsuletMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.14B$10.50B$6.02B$10.26BDividend YieldN/A1.89%5.67%4.76%P/E Ratio95.6020.6286.0326.56Price / Sales10.6936.65529.47192.34Price / Cash70.8925.0037.2660.57Price / Book18.213.3712.756.52Net Income$418.30M$210.63M$3.31B$276.43M7 Day Performance1.75%-2.89%0.79%-0.88%1 Month Performance-7.98%-0.43%6.67%3.48%1 Year Performance34.93%-6.89%77.62%30.15% Insulet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PODDInsulet4.6786 of 5 stars$314.52-1.8%$347.67+10.5%+34.9%$22.14B$2.07B95.603,900Positive NewsAnalyst ForecastBDXBecton, Dickinson and Company4.9406 of 5 stars$183.85-0.4%$213.09+15.9%-21.2%$52.91B$20.18B33.0774,000News CoveragePositive NewsAnalyst ForecastIDXXIDEXX Laboratories4.329 of 5 stars$630.56-0.3%$649.44+3.0%+29.4%$50.58B$3.90B52.5011,000News CoveragePositive NewsAnalyst ForecastEWEdwards Lifesciences4.8892 of 5 stars$77.25+1.3%$86.61+12.1%+8.6%$44.77B$5.44B11.1115,800News CoveragePositive NewsAnalyst UpgradeRMDResMed4.5724 of 5 stars$271.22+0.4%$294.20+8.5%+13.1%$39.57B$5.15B28.5210,600News CoveragePositive NewsAnalyst ForecastInsider TradeDXCMDexCom4.9472 of 5 stars$66.46-1.0%$99.11+49.1%-5.9%$26.31B$4.03B46.1510,300Analyst ForecastSTESTERIS4.8683 of 5 stars$245.37-1.5%$273.50+11.5%+3.9%$24.53B$5.46B37.5817,787Positive NewsHOLXHologic4.7597 of 5 stars$67.15-0.1%$79.38+18.2%-15.1%$14.95B$4.03B27.867,063Analyst UpgradeBAXBaxter International4.7033 of 5 stars$22.36+1.7%$30.11+34.7%-39.9%$11.29B$10.64B-74.5238,000Analyst ForecastOptions VolumeMASIMasimo4.2721 of 5 stars$142.94+1.1%$194.60+36.1%+2.9%$7.68B$2.09B-16.785,600Analyst ForecastGMEDGlobus Medical4.8473 of 5 stars$56.49+1.4%$87.64+55.1%-19.6%$7.52B$2.52B21.735,300Analyst Forecast Related Companies and Tools Related Companies Becton, Dickinson and Company Alternatives IDEXX Laboratories Alternatives Edwards Lifesciences Alternatives ResMed Alternatives DexCom Alternatives STERIS Alternatives Hologic Alternatives Baxter International Alternatives Masimo Alternatives Globus Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PODD) was last updated on 10/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
